T1	Participants 88 126	patients with metastatic breast cancer
T2	Participants 129 276	Three hundred twenty-five women with metastatic adenocarcinoma of the breast who had failed one prior chemotherapeutic regimen for advanced disease
T3	Participants 439 451	165 patients
